1 Combined oropharyngeal/nares and nasopharyngeal swab sampling remain effective for molecular 2 detection of SARS-CoV-2 Omicron variant 3 *Glenn Patriquin^{a,b}, Jason J. LeBlanc^{a,b,c,d}, Holly A. Gillis^e, Gregory R. McCracken^a, Janice J. Pettipas^f, and 4 Todd F. Hatchette^{a,b,c,d} 5 6 7 ^aDivision of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, 8 Halifax, Nova Scotia, Canada. 9 ^bDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada. ^cDepartment of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 10 11 ^dDepartment of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada. 12 ^ePublic Health, Nova Scotia Health, Halifax, Nova Scotia, Canada. 13 [†]Nova Scotia Provincial Public Health Laboratory Network (PPHLN), Halifax, Nova Scotia, Canada. 14 15 Key Words: COVID-19, SARS-CoV-2, Omicron, oropharyngeal, nares, nasopharyngeal, PCR, nose, throat 16 Running title: NP vs. OPN swabs for SARS-CoV-2 Omicron detection 17 Word count: 1069 18 Abstract: 189 19 *Corresponding author: Glenn Patriguin 20 Division of Microbiology, Department of Pathology and Laboratory 21 Medicine, Nova Scotia Health 22 Room 315, MacKenzie Building 23 5788 University Avenue, Halifax, Nova Scotia, B3H 1V8 24 Tel.: +1 902 473 7493, Fax: +1 902 473 6432 25 Email: glenn.patriquin@nshealth.ca

26

27

Summary

The world has experienced several waves of SARS-CoV-2 variants of concern (VoCs) throughout the COVID-19 pandemic since the first cases in December 2019. The Omicron VoC has increased transmission, compared to its predecessors, and can present with sore throat and other cold-like symptoms. Given the predominance of throat symptoms, and previous work demonstrating better sensitivity using antigen-based rapid detection tests when a throat swab is included in the standard nasal sampling, this quality improvement project sought to ensure ongoing suitability of both combined oropharyngeal/nares (OPN) and nasopharyngeal (NP) swab sampling used throughout the pandemic. Consenting participants meeting Public Health testing criteria (mostly symptomatic or a close contact of a known case) were enrolled, and paired NP and OPN swabs collections were subjected to nucleic acid amplification testing (NAAT). Comparing paired specimens from 392 participants sensitivity of NP swabs was 89.1% (95% CI, 78.8-94.9), and that of OPN was 98.4% (95% CI: 90.9->99.9) (p-value 0.052). This project demonstrated that both NP and combined OPN swabs detected the Omicron variant with similar sensitivity by NAAT, supporting the continued use of either swab collection for SARS-CoV-2 molecular detection.

Short communication

Since COVID-19 was first described in December 2019, several SARS-CoV-2 variants of concern (VoCs) have been detected, each with unique properties, both in terms of symptomatology and transmissibility. Prior to the emergence of VoCs, RT-PCR of testing nasopharyngeal (NP) swabs was the gold standard approach to testing in community and hospitalized patients, with the addition of lower tract specimens to increase sensitivity in those with pulmonary disease¹. Early in the global response, the reduced availability of NP swabs necessitated the validation of several combined oropharyngeal/nares (OPN) swabs as an alternative sampling method, which demonstrated acceptable performance when compared to the NP^{2,3}. Recently the Omicron VoC (lineage B.1.1.529)⁴ has become predominant in many regions in the world and is notable for its increased transmissibility, reduced vaccine effectiveness^{5,6}, and possible differences in tissue tropism^{7–9}. The propensity to cause sore throat and cold-like symptoms¹⁰, along with previous work showing improved sensitivity with inclusion of a throat sample in combination with nasal sampling for use with antigen-based rapid testing devices (Ag-RDTs)^{11,12}, prompted this quality improvement initiative.

Community members who met eligibility criteria for molecular diagnostic testing by Public Health (Table S1) were asked to participate in this project. Participants were adults recruited from one of two testing streams during a four-day period in January of 2022, in Nova Scotia, Canada. Enrollment was either facilitated by Public Health through the Public Health Mobile Testing Unit deployed for outbreak investigations in multiple communities, or through urban-based COVID-19 testing centres. In both streams, participants had NP sampling for nucleic acid amplification testing (NAAT), using a standardized sampling technique with a flocked swab (https://vimeo.com/516853275/c67017fd3a), which was placed in viral transport media (VTM) (Copan Diagnostics, Inc., (Murrietta, CA), or AccuViral Collection Kit, (AccuGene, San Diego, CA)). Following verbal consent, an additional combined OPN swab

was collected as previously described^{2,3,13}, using a CLASSIQSwab fiber-tip swab from Copan Italia (Brescia, Italy), placed into the same type of VTM.

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

NP and OPN samples were immediately transported to a central laboratory and refrigerated at 4° Celsius, where NAAT was performed within 12h according to manufacturer instructions. Initially, both NP and OPN samples were tested using the Aptima SARS-CoV-2 Assay on the Panther System (Hologic Inc., San Diego, CA). NP and OPN swabs with negative Panther results were confirmed as negative with the SARS-CoV-2 Test on the Cobas 6800 instrument (Roche Diagnostics, Rotkreuz, Switzerland). NP or OPN swabs with positive results, as well as the paired specimen regardless of its result, were subsequently tested using both the Roche 6800 assay and the Xpert Xpress SARS-CoV-2 test (Cepheid, Sunnyvale, CA). Swab result was compared to a consensus reference standard derived from all NAAT test results. For each swab, a positive result was defined as SARS-CoV-2 detection in at least two NAATs (Table S2). To categorize swab results as true positive, true negative, false positive, and false negative results (to determine sensitivity and specificity), each swab was compared to the case result, McNemar's test with Yate's correction established at the level of the individual. (https://www.omnicalculator.com/) was used to determine statistical significance between NP and OPN swab collections. This project was deemed a quality improvement initiative and was exempt from Research Ethics Board review (file number 1027644).

Overall, 392 participants with paired NP and OPN samples were analyzed, with concurrent results between swab types seen for the majority of individuals (Table). The overall positivity rate was 16.3%, with 328 individuals negative by both swab types, and 56 with positive results from both swab types. Eight people had conflicting results, with one SARS-COV-2 detection identified by NP alone, and seven detected by OPN alone. Sensitivity and specificity were 89.1% (95% confidence interval (CI): 78.8-94.9%) and 100% (95% CI: 92.5-100), and 98.4% (95% CI: 90.9->99.9%) and 100% (95% CI: 93.1-100), for NP and OPN swabs, respectively. However, this difference between the swab types was not statistically

significant (p-value, 0.052). All OPN samples with Ct values <32 were submitted for next-generation sequencing at the National Microbiology Laboratory (NML) (Winnipeg, Manitoba). Of 59 samples submitted, four sequencing reactions failed, and the remaining 55 samples were characterized as the VoC, Omicron (50 of the BA.1 lineage, and five of the BA.1.1 lineage).

The COVID-19 pandemic has been fraught with various challenges; each wave uniquely testing our ability to detect, contain, and prevent infection. With Omicron, questions have been raised regarding altered tissue tropism, which caused people to question the optimal anatomical location for SARS-CoV-2 detection. In this quality project, there was no significant difference between NP or OPN specimens for the detection of SARS-CoV-2 when using NAAT methods.

This conclusion differs from our recent study in which the sensitivity of Ag-RDTs for detecting SARS-CoV-2 was higher when sampling the throat and nose (versus nasal sampling alone). However, the results of that study are not directly comparable to this population because the current project compared the nasopharynx and the oropharynx/nares, whereas the Ag-RDT study compared bilateral nares swabbing with an OPN swab. It may be that the anatomical proximity of the nasopharynx to the oropharynx rendered a difference between sampling these sites insignificant. In addition, perhaps NAAT testing, being more sensitive than Ag-RDT testing was not subject to noticeable differences between the sites. In this project, although not significant, there were some cases detected by OPN that were missed by NP sampling. It is possible that some of these results reflect the difficulty in performing an NP swab consistently, as compared to the relative ease of performing an OPN swab; however, given a lack of a reliable molecular host target for sample quality, the possibility of discrepant results based on differences in anatomical sites is also possible 1-9.

This project was limited in several ways. As it was a quality initiative, clinical information for participants was not available, therefore symptomatology, timing of swab collection from recent

exposures, and the impact of co-morbid conditions or immunization status could not be established.

Also, despite policies and training in the standardization of performing NP swabs, the quality of the technique could not be directly assessed.

Ultimately, despite evidence indicating that combined sampling of the throat and nares can significantly increase SARS-CoV-2 detection by Ag-RDTs compared to nasals swabs, the performance characteristics of OPN swabs did not differ from the reference NP sampling method for NAAT detection of SARS-CoV-2. Importantly, this work demonstrates the ongoing suitability of either NP or OPN swab for molecular detection of SARS-CoV-2, even if Omicron potentially has altered tissue tropism.

Acknowledgements

The authors thank the constant efforts of those working in the COVID-19 Testing Centres and the Public Health Mobile Units for their support in this project. Your dedication and enthusiasm for projects such as these are instrumental for the ongoing care of the community. The authors would also like to thank front line staff in the Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, for their support for this project and unwavering efforts throughout the pandemic. Thank you to the National Microbiology Laboratory for providing surveillance sequencing data.

Table. SARS-CoV-2 nucleic acid amplification test results of paired nasopharyngeal and

oropharyngeal/nares swabs.

129

130

131

Number of participants

Positive by NP and OPN	56
Positive by NP only	1
Positive by OPN only	7
Negative by NP and OPN	328
p-value (NP vs. OPN)*	0.052

*McNemar's test with Yate's correction; NP, nasopharyngeal; OPN, oropharyngeal/nares.

References

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

Bwire GM, Majigo MV, Njiro BJ, Mawazo A. Detection profile of SARS□CoV□2 using 1. RT□PCR in different types of clinical specimens: A systematic review and meta □ analysis. J Med Virol. 2021;93(2):719-725. doi:10.1002/jmv.26349 2. LeBlanc JJ, Heinstein C, MacDonald J, Pettipas J, Hatchette TF, Patriquin G. A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2. Journal of Clinical Virology. 2020;128:104442. doi:10.1016/j.jcv.2020.104442 Patriquin G, Davis I, Heinstein C, MacDonald J, Hatchette TF, LeBlanc JJ. Exploring 3. alternative swabs for use in SARS-CoV-2 detection from the oropharynx and anterior nares. Journal of Virological Methods. 2020;285:113948. doi:10.1016/j.jviromet.2020.113948 4. World Health Organization. Tracking SARS-CoV-2 variants. Accessed January 16, 2022. https://www.who.int/emergencies/what-we-do/tracking-SARS-CoV-2-variants Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine 5. against Omicron Variant in South Africa. N Engl J Med. Published online December 29, 2021:NEJMc2119270. doi:10.1056/NEJMc2119270 Araf Y, Akter F, Tang Y dong, Fatemi R, Parvez MdSA, Hossain MdG. Omicron variant of 6. SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. Journal of Medical Virology. 2022; Epub ahead of print. doi:10.1002/jmv.27588

- 7. CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) Variant United
- 155 States, December 1–8, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(50):1731-1734.
- 156 doi:10.15585/mmwr.mm7050e1
- 157 8. Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nat*
- 158 *Med.* 2021;27(5):892-903. doi:10.1038/s41591-021-01296-8
- 159 9. Marais G, Hsiao N yuan, Iranzadeh A, et al. Saliva Swabs Are the Preferred Sample for
- 160 Omicron Detection. MedRxiv Infectious Diseases (except HIV/AIDS); 2021.
- doi:10.1101/2021.12.22.21268246
- 162 10. Iacobucci G. Covid-19: Runny nose, headache, and fatigue are commonest symptoms of
- omicron, early data show. *BMJ*. Published online December 16, 2021:n3103.
- 164 doi:10.1136/bmj.n3103
- 165 11. Adamson B, Sikka R, Wyllie AL, Premsrirut P. Discordant SARS-CoV-2 PCR and Rapid
- 166 Antigen Test Results When Infectious: A December 2021 Occupational Case Series.
- Infectious Diseases (except HIV/AIDS); 2022. doi:10.1101/2022.01.04.22268770
- 168 12. Goodall BL, LeBlanc JJ, Hatchette TF, Barrett L, Patriquin G. Investigating Sensitivity of
- Nasal or Throat (ISNOT): A Combination of Both Swabs Increases Sensitivity of SARS-
- 170 CoV-2 Rapid Antigen Tests. *MedRxiv Infectious Diseases (except HIV/AIDS)*; 2022.
- 171 doi:10.1101/2022.01.18.22269426
- 13. LeBlanc JJ, Pettipas J, Di Quinzio M, Hatchette TF, Patriquin G. Reliable detection of
- SARS-CoV-2 with patient-collected swabs and saline gargles: A three-headed comparison
- on multiple molecular platforms. *Journal of Virological Methods*. 2021;295:114184.
- 175 doi:10.1016/j.jviromet.2021.114184

176

177

- 178 **Table S1.** Provincial Public Health eligibility criteria for COVID-19 testing by polymerase chain reaction,
- 179 at the time of data collection.

People who have symptoms or have been identified as close contacts AND are one of the following:

- 50 years and over
- Unvaccinated (less than full vaccine series) and age 12 or older
- Live or work in the following congregate settings:
 - Long-term care home
 - o Residential care facilities
 - Corrections
 - Shelters and transition houses
 - Acute care settings
- Adult First Nations and African Nova Scotians
- Front line Health Care Workers with direct patient care (eg family physicians, nurse practitioners, dentist) and First Responders
- Adults 18-49 year with one or more risk factors for severe disease:
 - Obesity (BMI >30 kg/m2)
 - Type 1 or 2 diabetes mellitus
 - Chronic lung disease, including poorly controlled asthma (e.g. on medication or hospitalization within the past 12 months)
 - Chronic kidney disease, including those on dialysis
 - Down Syndrome
 - o Motor Neuron Disease, Multiple Sclerosis, Myasthenia Gravis, Huntington's Disease
 - o Immunocompromised or receiving immunosuppressive therapy
- Children and youth under age 18 with any of the following conditions:
 - history of prematurity < 29 weeks
 - Chronic lung disease including chronic lung disease of prematurity, cystic fibrosis, and severe asthma
 - Down Syndrome
 - o Motor Neuron Disease, Multiple Sclerosis, Myasthenia Gravis
 - Obesity (BMI >30kg/m2)
- Pregnant

days

180

181

182

- 2. Testing required for medical procedure
- 3. Partially or unvaccinated travelers who need 2 negative PCR tests to stop isolating after at least 7

Table S2. Discrepant results between NP and OPN swab collections.

183

184 185

186

187

	NP swab									OPN swab								
Sample	Panther			6800		Xpert			Panther			6800			Xpert			
	RLU	Result	Ct Orf1a/b	Ct E gene	Result	Ct E gene	Ct N2 gene	Result	Overall Result	RLU	Result	Ct Orf1a/b	Ct E gene	Result	Ct E gene	Ct N2 gene	Result	Overall Result
1	906	POS	41.6	42.7	POS	0	0	NEG	POS	NEG	NEG	0	0	NEG	0	0	NEG	NEG
2	NEG	NEG	0	0	NEG	0	37.87	POS	NEG	812	POS	0	41.7	POS	0	37.25	POS	POS
3	NEG	NEG	39	41.8	POS	0	0	NEG	NEG	1265	POS	35.1	38.3	POS	35.76	37.1	POS	POS
4	NEG	NEG	0	0	NEG	0	0	NEG	NEG	1227	POS	38.6	40.7	POS	0	35.48	POS	POS
5	NEG	NEG	0	0	NEG	0	0	NEG	NEG	1264	POS	33.3	35.7	POS	31.15	32.62	POS	POS
6	NEG	NEG	0	0	NEG	0	0	NEG	NEG	1300	POS	25.4	27.6	POS	27.31	27.55	POS	POS
7	NEG	NEG	0	0	NEG	0	0	NEG	NEG	1305	POS	23.8	26.2	POS	23.52	23.9	POS	POS
8	NEG	NEG	0	0	NEG	0	0	NEG	NEG	1306	POS	24.5	26.7	POS	24.83	25.09	POS	POS

Abbreviations: cycle threshold (Ct); relative light unit (RLU); nasopharyngeal (NP); oropharyngeal/bilateral nares (OPN).